Malaria Vaccine Branch, US Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.
MSP1 is the major surface protein on merozoites and a prime candidate for a blood stage malaria vaccine. Preclinical and seroepidemiological studies have implicated antibodies to MSP1 in protection against blood stage parasitaemia and/or reduced parasite densities, respectively. Malaria endemic areas have multiple strains of Plasmodium falciparum circulating at any given time, giving rise to complex immune responses, an issue which is generally not addressed in clinical trials conducted in non-endemic areas. A lack of understanding of the effect of pre-existing immunity to heterologous parasite strains may significantly contribute to vaccine failure in the field. The purpose of this study was to model the effect of pre-existing immunity to MSP142 on the immunogenicity of blood-stage malaria vaccines based on alternative MSP1 alleles.
Inbred and outbred mice were immunized with various recombinant P. falciparum MSP142 proteins that represent the two major alleles of MSP142, MAD20 (3D7) and Wellcome (K1, FVO). Humoral immune responses were analysed by ELISA and LuminexTM, and functional activity of induced MSP142-specific antibodies was assessed by growth inhibition assays. T-cell responses were characterized using ex vivo ELISpot assays.
Analysis of the immune responses induced by various immunization regimens demonstrated a strong allele-specific response at the T cell level in both inbred and outbred mice. The success of heterologous regimens depended on the degree of homology of the N-terminal p33 portion of the MSP142, likely due to the fact that most T cell epitopes reside in this part of the molecule. Analysis of humoral immune responses revealed a marked cross-reactivity between the alleles. Functional analyses showed that some of the heterologous regimens induced antibodies with improved growth inhibitory activities.
The development of a more broadly efficacious MSP1 based vaccine may be hindered by clonally imprinted p33 responses mainly restricted at the T cell level. In this study, the homology of the p33 sequence between the clonally imprinted response and the vaccine allele determines the magnitude of vaccine induced responses.
MSP1 是裂殖子表面的主要蛋白,是血阶段疟疾疫苗的主要候选物。临床前和血清流行病学研究表明,针对 MSP1 的抗体分别在预防血期寄生虫血症和/或降低寄生虫密度方面具有保护作用。疟疾流行地区在任何特定时间都有多种恶性疟原虫株循环,导致复杂的免疫反应,这是在非流行地区进行的临床试验中通常未解决的问题。对异源寄生虫株预先存在的免疫的影响缺乏了解,可能会导致该疫苗在现场的失败。本研究旨在模拟针对 MSP142 的预先存在的免疫对基于替代 MSP1 等位基因的血期疟疾疫苗的免疫原性的影响。
近交系和远交系小鼠用各种重组恶性疟原虫 MSP142 蛋白免疫,这些蛋白代表 MSP142 的两个主要等位基因,MAD20(3D7)和 Wellcome(K1、FVO)。通过 ELISA 和 LuminexTM 分析体液免疫反应,并通过生长抑制测定评估诱导的 MSP142 特异性抗体的功能活性。使用体外 ELISpot 测定来描述 T 细胞反应。
对各种免疫方案引起的免疫反应的分析表明,在近交系和远交系小鼠中,T 细胞水平上存在强烈的等位基因特异性反应。异源方案的成功与否取决于 MSP142 的 N 端 p33 部分的同源性程度,这可能是因为大多数 T 细胞表位都位于该分子的这一部分。对体液免疫反应的分析表明,等位基因之间存在明显的交叉反应。功能分析表明,一些异源方案诱导的抗体具有改善的生长抑制活性。
基于 MSP1 的更广泛有效的疫苗的开发可能会受到主要在 T 细胞水平上受到克隆印迹的 p33 反应的阻碍。在这项研究中,克隆印迹反应和疫苗等位基因之间的 p33 序列的同源性决定了疫苗诱导反应的大小。